Antithrombotic coating for drug eluting medical devices

Details Antithrombotic coating for drug eluting medical devices Antithrombotic coating for drug eluting medical devices

2011-05-24

2011-05-24

Wax, Robert A (Department: 1619)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

C514S772500

Reexamination Certificate

active

07947302

ABSTRACT:
Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.

REFERENCES:
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 3959078 (1976-05-01), Guire
patent: 4350160 (1982-09-01), Kolesov et al.
patent: 4368736 (1983-01-01), Kaster
patent: 4624257 (1986-11-01), Berggren et al.
patent: 4722906 (1988-02-01), Guire
patent: 4733665 (1988-03-01), Palmaz
patent: 4739762 (1988-04-01), Palmaz
patent: 4776337 (1988-10-01), Palmaz
patent: 4917090 (1990-04-01), Berggren et al.
patent: 4917091 (1990-04-01), Berggren et al.
patent: 5229172 (1993-07-01), Cahalan et al.
patent: 5234447 (1993-08-01), Kaster et al.
patent: 5308641 (1994-05-01), Cahalan et al.
patent: 5350800 (1994-09-01), Verhoeven et al.
patent: 5415938 (1995-05-01), Cahalan et al.
patent: 5837313 (1998-11-01), Ding et al.
patent: 5924997 (1999-07-01), Campbell
patent: 6099562 (2000-08-01), Ding et al.
patent: 6120536 (2000-09-01), Ding et al.
patent: 6153252 (2000-11-01), Hossainy et al.
patent: 6245026 (2001-06-01), Campbell et al.
patent: 7195640 (2007-03-01), Falotico et al.
patent: 7247313 (2007-07-01), Roorda et al.
patent: 2003/0108588 (2003-06-01), Chen et al.
patent: 2003/0181973 (2003-09-01), Sahota
patent: 2004/0002755 (2004-01-01), Fishell
patent: 2005/0176678 (2005-08-01), Horres et al.
patent: 2005/0238686 (2005-10-01), Hossainy et al.
patent: 2007/0048350 (2007-03-01), Falotico et al.
patent: 2007/0196679 (2007-08-01), Moriyama et al.
patent: 136202 (2003-11-01), None
patent: WO 03/024455 (2003-03-01), None
patent: WO 03/035131 (2003-05-01), None
patent: WO 2005-016187 (2005-02-01), None
Ajroldi, G. et al., “Fluoroelastomers-dependence of relaxation phenomena on compositions”, Polymer, 30, No. 12, (1989): 2180-2187.
Berk, B.C. et al., “Pharmacologic Roles of Heparin and Glucocorticoids to Prevent Restenosis After Coronary Angioplasty”, J. Am. Coll. Cardio. vol. 17, No. 6, pp. 111B-117B, (1991).
Beutler, E. “Cladribine (2-chlorodeoxyadenosine)”, The Lancet, vol. 340, p. 952 (Oct. 1992).
Brehm, B., et al. “β-Blockers of the Third Generation Inhibit Endothelin-1 Liberation, mRNA production and Proliferation of Human Coronary Smooth Muscle and Endothelial Cells”, Journal of Cardiovascular Pharmacology, 36 (Suppl. 1):S401-S-403 (2000).
Brehm, B., et al. “Chronically Elevated Endothelin-1 Concentrations Modulate the β-Adrenergic Receptor System In Vitro and In Vivo”, Journal of Cardiovascular Pharmacology, 36 (Suppl. 1):S157-159 (2000).
Campbell & Campbell, “Phenotypic Modulation of Smooth Muscle Cells in Primary Culture”, (Table of Contents), Chapter 2, vol. 1, pp. 39-52 (1985).
Carrera et al., “Potent Toxicity of 2-Chlorodeoxyadenosine . . . ”J. Clin. Invest 86:1480-1488, 1990.
Carson, D.A. et al., “Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes”, Blood 62: 737-743, 1983.
Carson, D., et al. “DNA Strand Breaks, NAD Metabolism, and Programmed Cell Death”, Experimental Cell Research 164 p. 273-281 (1986).
Chang, M.W. et al., “Adenovirus-mediated Over-expression of the Cyclin/Cyclin-dependent Kinase Inhibitor, p21 Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat Carotid Artery Model of Balloon Angioplasty”, J. Clin. Invest. vol. 96, pp. 2260-2268, (1995).
Clowes, A.W. et al., “Suppression by heparin of smooth muscle cell proliferation in injured arteries”, Nature, vol. 265, pp. 625-626, (1977).
Clowes, A.W. et al., “Kinetics of Cellular Proliferation after Arterial Injury”, Laboratory Investigation, vol. 52, No. 6, pp. 611-616, (1985).
Clowes, A.W. et al., “Kinetics of Cellular Proliferation after Arterial Injury IV. Heparin Inhibits Rat Smooth Muscle Mitogenesis and Migration”, Circulation Research, vol. 58, No. 6, pp. 839-845, (1986).
Colburn, M.D. et al., “Dose responsive suppression of myointimal hyperplasia by dexamethasone”, J. Vasc. Surg. vol. 15, No. 3, pp. 510-518, (1992).
Currier, J.W. et al., “Colchicine Inhibits Restenosis Afer Iliac Angioplasty in the Atherosclerotic Rabbit”, Supplement II Circulation vol. 80, No. 4, II-66, (1989).
Deroanne et al., “Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling”, Oncogene 21 (3): 427-436, 2000.
Edelman, E., et al. “Pathobiologic Responses to Stenting”, American journal of Cardiology vol. 91, Issue 7, Suppl. 1 (Apr. 1998) pp. 4E-6E.
Farb, A. et al., “Vascular Smooth Muscle Cell Cytotoxicity and Sustained Inhibition of Neointimal Formation by Fibroblast Growth Factor 2-Saporin Fusion Protein”, Circ. Res. vol. 80, No. 4, pp. 542-550, (1997).
Ferns, G.A. et al., “Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF”, Science, vol. 253, pp. 1129-1132, (1991).
Franklin, S., et al. “Pharmacologic Prevention of Restenosis After Coronary Angioplasty: Review of the Randomized Clinical Trials”, Coronary Artery Disease, vol. 4, No. 3 (Mar. 1993).
Fukuyama J., et al., “Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet”, European Journal of Pharmacology 318, pp. 327-332, (1996).
Guyton, J.R. et al., “Inhibition of Rat Arterial Smooth Muscle Cell Proliferation by Heparin”, Circulation Research, vol. 46, No. 5, pp. 625-634, (1980).
Hanson, S.R. et al., “Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone”; Proc. Natl. Acad. Sci. USA (May 1988) 85: 3184-3188.
Hansson, G.K., et al., “Interferon-γ Inhibits Arterial Stenosis After Injury” Circulation, vol. 84, No. 3, pp. 1266-1272, (1991).
Jonasson, L. et al., “Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury”, Proc. Natl. Acad. Sci. USA vol. 85, pp. 2303-2306, (1988).
Lang, R., et al. “Effects of Okadaic Acid and ATPγS on Cell Length and CA2+—Channel Currents Recorded in single . . . ”, Br. J. Pharmacol. 104, p. 331-336 (1991).
Liu, M.W. et al., “Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit”, Circ. vol. 81, No. 3, pp. 1089-1093, (1990).
Lundergan, C.F. et al., “Peptide Inhibition of Myointimal Proliferation by Angiopeptin, a . . . ”, JACC vol. 17(Supp. B), No. 6. pp. 132B-136B, (1991).
Majesky, M.W. et al., “Heparin Regulates Smooth Muscle S Phase Entry in the Injured Rat Carotid Artery”, Circ. Res. vol. 61, No. 2, pp. 296-300, (1987).
Mak and Topol, “Clincial Trials to Prevent Restenosis after Percutaneous Coronary Revascularization”, Annals N.Y. Academy of Sci., 255-288, 1997.
Marx, S.O., et al., “Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells”, Circ. Res., vol. 76, No. 3, pp. 412-417, (1995).
Mintz et al., “Limitations of Angiography in the Assessment of Plaque Distribution in Coronary Artery Dis

Affiliated with

Also associated with

Rating

Antithrombotic coating for drug eluting medical devices does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antithrombotic coating for drug eluting medical devices, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antithrombotic coating for drug eluting medical devices will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2697588